HK Stock Market Move | CARSGEN-B (02171) rises over 4%; research findings on Kailimei were recently presented as a poster at the ESMO Annual Meeting

CARSGEN-B (02171) rose over 4%, up 4.21% as of press time at HK$10.9, with turnover of HK$14.0204 million. On the news front, CARSGEN-B recently announced that the preliminary results of a clinical trial (CT041-CG4010, NCT06857786) conducted in China of Kailimei (satri-cel injection, product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2) for consolidation therapy following adjuvant treatment in patients with Claudin18.2-positive gastric/gastroesophageal junction cancer after radical surgery were presented as a poster at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on October 25, 2026 (Sunday) from 12:00-12:45 Central European Summer Time (CEST). Previously, on June 22, 2026, CARSGEN-B received notice from the National Medical Products Administration (NMPA) approving the new drug application for its independently developed Claudin18.2 autologous humanized CAR-T cell therapy product Kailimei (satri-cel injection) for the treatment of Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric/gastroesophageal junction adenocarcinoma that has failed at least second-line therapy. It is reported that Kailimei is the world's first approved CAR-T cell therapy product for the treatment of solid tumors.